CDP: state-controlled drugmaker with modest upside, low conviction given liquidity and earnings-quality flags
Intrinsic value VND 13,564 vs market VND 12,100 — implied upside 12.1% (model confidence: low).
Business Overview
Công ty Cổ phần Dược phẩm Trung ương Codupha (CDP) is a UPCOM-listed pharmaceutical manufacturer and distributor operating in the Vietnamese healthcare/consumer sector, classified under ICB 3 'Dược phẩm'. The firm reported revenue of VND 3,285.3 bn in 2025 and has notable scale in the domestic generics/OTC market. Ownership is concentrated: Tổng Công ty Dược Việt Nam (a state-owned pharmaceutical conglomerate) holds 66.35%, followed by institutional financial shareholders (DSC 14.87%, NTP AM 8.25%). CDP trades with effectively zero foreign room (foreign_room 0.0) and low average turnover (avg_volume_2w 1,124 shares), reflecting limited free float and liquidity on UPCOM.
Investment Thesis
CDP's valuation implies modest upside: the blended model yields an intrinsic value of VND 13,564 per share vs the match price of VND 12,100, a 12.1% gap. On fundamentals, the company shows improvement in profitability: net profit increased from VND 9.3 bn in 2023 to VND 35.4 bn in 2025, and ROE is 15.9% with an EPS of approximately VND 1,944. The dividend yield is meaningful at 7.4%, consistent with the SOE legacy of steady cash distributions.
Offsetting these positives are structural and execution risks. Reported margins remain thin (gross margin 6.6%, EBIT margin 1.75%, net margin 1.08%), and ROA is only 1.6%. Leverage metrics look elevated on a reported basis (Debt/Equity 9.6x) which, combined with net debt of roughly VND 961.5 bn, constrains balance-sheet flexibility. The model flags low earnings quality and illiquidity; trading liquidity and zero foreign room raise the effective investable free float and exit risk for institutional buyers. Finally, our model confidence is low, reducing conviction in the 12.1% implied upside.
Valuation Commentary
Blend of a 10-year FCF DCF (70%) and a PE-based terminal valuation (30%), calibrated by isotonic mapping to peer outcomes.
- DCF inputs: base FCF VND 48,702,739,538 and WACC 10%; terminal growth 4%; TV accounts for 57.07% of enterprise value.
- PE inputs: fair PE 17.69 with a PE cap of 25; standalone PE intrinsic from the model is VND 34,386.3 per share before blending.
- Blend weights: 70% DCF / 30% PE produces the blended intrinsic VND 13,564 per share.
- Balance-sheet and cash: model net debt ~VND 961.5 bn reduces enterprise value to equity value.
- Sanity flags: illiquid stock, illiquid_upside_capped and low_earnings_quality lower model confidence to 'low'.
The blended intrinsic value implies a 12.1% upside but model confidence is low due to illiquidity and earnings-quality flags; the DCF leg produced an anomalous negative 'dcf_intrinsic' (-6,443.4) while the PE leg produced a much higher raw intrinsic (VND 34,386.3), hence the heavy reliance on blend calibration. Treat the VND 13,564 target as a probabilistic reference rather than a high-confidence fair value.
Bull vs Bear
- Improving profitability: net profit rose from VND 9.3 bn (2023) to VND 35.4 bn (2025), supporting an EPS ~VND 1,944 and ROE 15.9%.
- Attractive cash return: dividend yield of 7.4% provides current-income support to returns even if capital appreciation is muted.
- Reasonable valuation on multiples: P/E 6.2x and P/B 0.97x suggest limited downside from current levels if operations remain stable.
- Liquidity and marketability: average 2-week volume only 1,124 shares and zero foreign room increase execution risk and may cap rerating despite intrinsic upside.
- Low earnings quality and model sanity flags increase the probability of earnings volatility or one-off items that could reverse recent profit growth (earnings_quality 27.4).
- High reported leverage (Debt/Equity 9.6x) and substantial net debt (~VND 961.5 bn) constrain reinvestment and make the company sensitive to working-capital swings.
- Concentrated SOE ownership (66.35%) limits free-float catalysts and could prioritize stakeholder objectives (e.g., employment, supply security) over margin expansion.
Sector Context
The Vietnamese pharmaceutical subsector is fragmented, with many local generics players and a handful of larger SOE-related producers/distributors. SBV credit growth quotas and banking funding conditions can affect working-capital financing for mid-sized pharma firms; banks may also hold VAMC exposure that impacts sector lending. VAS accounting and government procurement practices can cause timing differences between reported revenue and cash. Peers show a wide dispersion in implied upside (sector median upside ~12.0%), indicating heterogeneous business models and valuation multiples across the subsector. For UPCom-listed names, low liquidity and limited foreign participation are common and often compress valuation multiples relative to HNX/HOSE peers.
Risk Factors
- Illiquidity: avg_volume_2w 1,124 shares and UPCOM listing make entry/exit costly and can amplify short-term price moves.
- Earnings quality: earnings_quality score 27.4 and model sanity flag 'low_earnings_quality' suggest reliance on non-recurring items or accounting timing effects.
- High leverage: Debt/Equity 9.6x and net debt ~VND 961.5 bn increase refinancing and cash-flow risk if margins weaken.
- Concentrated ownership: state parent holds 66.35%, limiting free float and potential for minority-friendly corporate actions; also exposes the company to SOE policy objectives.
- Zero foreign room: foreign_room 0.0 prevents incremental demand from foreign investors and narrows buyer base.
- Regulatory and procurement risk: price controls, tender competition in public hospitals, and differences under VAS accounting could pressure margins.
Catalysts
- Sustained margin expansion and recurring profit growth reported over consecutive quarters that improves earnings-quality perception.
- Corporate actions that increase free float or open foreign ownership (e.g., share re-allocation or divestment by state parent).
- Material debt reduction or conversion that reduces Debt/Equity from current reported 9.6x and the net-debt burden (~VND 961.5 bn).
- Improved liquidity or inclusion on a higher-profile trading venue that reduces the illiquidity discount.
Forensic Assessment
No Beneish M-Score is provided and explicit mscore fields are null. However, the model raised 'low_earnings_quality' as a sanity flag and the earnings_quality metric is 27.4 (relatively low), which is the principal forensic concern. There are no explicit red flags in the forensic.summary, but low earnings-quality combined with atypical model outputs (negative dcf_intrinsic vs very high pe_intrinsic) warrants caution and further forensic review of one-off items, related-party transactions, and working-capital accounting.
Track Record
Model track record: 9 years with a hit rate of 62.5% for directional calls (years where >10% upside matched next-year direction). Historical average upside on successful calls is high (avg_upside_pct 131.1%), but sample size is limited and past performance does not guarantee future accuracy. Given the model's 'low' confidence for this stock, historical hit rate provides only partial comfort.
Written by a language model on 2026-08-10 from this page’s own model outputs and financial statements, and may quote figures from that date. Descriptive analysis, not investment advice — no buy, sell or hold recommendation is given or implied.